According to a recent LinkedIn post from Function Health, the company is drawing attention to the role of prostate-specific antigen, or PSA, as a key laboratory marker for men’s prostate health. The post notes that PSA testing is among more than 160 lab tests available to Function Health members, positioning the offering as a way to track early changes in health metrics.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that Function Health is emphasizing preventative and data-driven healthcare, with a focus on continuous monitoring rather than symptom-based intervention. For investors, this focus may indicate an effort to deepen engagement with male members, broaden the addressable market in men’s health, and differentiate its membership model within the growing consumer diagnostics and longevity-testing segment.
By highlighting PSA within a larger test panel, Function Health appears to be promoting the breadth of its lab-testing platform as a value proposition. This approach could support higher perceived membership value, potentially aiding in subscription retention and cross-selling of additional health services over time in a competitive digital health landscape.